clinical trial · NCT06591793
Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
Usher Syndrome, Type 1BAAVB-081
brief summary
The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
started
Jul 2, 2024
primary completion
Jul 1, 2025
completion
Jul 1, 2029
last updated
May 2, 2025
official title
A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol